Floatz logo

Irinotecan

Localized Transitional Cell Cancer of the Renal Pelvis and Ureter

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Localized Transitional Cell Cancer of the Renal Pelvis and Ureter cohort.

Asset / SponsorPhaseRating
VINBLASTINE
University of Southern California
Phase 3BB
PEGFILGRASTIM
University of Southern California
Phase 2B
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 2CCC
Vorinostat
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →